Shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC - Get Free Report) rose 3.2% on Friday . The stock traded as high as $20.40 and last traded at $20.02. Approximately 4,808 shares were traded during trading, a decline of 86% from the average daily volume of 33,283 shares. The stock had previously closed at $19.40.
Singular Genomics Systems Trading Up 3.2 %
The company has a debt-to-equity ratio of 0.04, a current ratio of 7.37 and a quick ratio of 6.67. The business has a fifty day moving average of $18.19 and a 200-day moving average of $12.35. The stock has a market capitalization of $50.25 million, a price-to-earnings ratio of -0.57 and a beta of 1.82.
Singular Genomics Systems (NASDAQ:OMIC - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) earnings per share for the quarter, beating the consensus estimate of ($8.05) by $1.33. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative return on equity of 57.87%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.74 million.
Institutional Investors Weigh In On Singular Genomics Systems
A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC grew its stake in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,962 shares of the company's stock after purchasing an additional 1,193 shares during the period. Geode Capital Management LLC owned about 0.72% of Singular Genomics Systems worth $282,000 as of its most recent SEC filing. Institutional investors own 65.80% of the company's stock.
Singular Genomics Systems Company Profile
(
Get Free Report)
Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.
Featured Stories
Before you consider Singular Genomics Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Singular Genomics Systems wasn't on the list.
While Singular Genomics Systems currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
